Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)

  • STATUS
    Recruiting
  • End date
    Jan 27, 2022
  • participants needed
    18
  • sponsor
    MedSIR
Updated on 27 January 2021

Summary

This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate the efficacy and safety of INCMGA00012 in Advanced Penile Squamous Cell Carcinoma

Description

Men age 18 years with locally advanced unresectable or metastatic PSqCC stage 4 (i.e. T4 or N3 or M1) that are presenting with radiologic progression of disease (PD) following or not standard treatment with chemotherapy.

After signing the ICF and confirmed eligibility, patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle, once every four weeks for up to 2 years.

Patients will receive treatment until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.

Patients discontinuing the study treatment period will enter a post-treatment follow-up period during which survival and new anti-cancer therapy information will be collected every 3 months ( 14 days) from the last dose of investigational product until the end of study (EoS).

Details
Condition Malignant neoplasm of penis
Treatment INCMGA0012
Clinical Study IdentifierNCT04231981
SponsorMedSIR
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you male?
Do you have Malignant neoplasm of penis?
Do you have any of these conditions: Do you have Malignant neoplasm of penis??
Do you have any of these conditions: Do you have Malignant neoplasm of penis??
Do you have any of these conditions: Do you have Malignant neoplasm of penis??
Do you have any of these conditions: Do you have Malignant neoplasm of penis??
Do you have any of these conditions: Do you have Malignant neoplasm of penis??
Do you have any of these conditions: Do you have Malignant neoplasm of penis??
Patients have been informed about the nature of study, and have agreed to participate in the study, and signed the informed consent form (ICF) prior to participation in any study-related activities
Male patients 18 years of age at the time of signing ICF
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
Life expectancy 12 weeks
Histologically-proven PSqCC
Locally advanced unresectable or metastatic stage 4 PSqCC that is not amenable to resection with curative intent (T4 or N3 or M1)
Radiological evidence of locally advanced or metastatic disease
Patients must have measurable disease or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1 criteria
Patients must agree to provide a tumor tissue sample from a metastatic site or the primary tumor at the time of study entry, with the exception of patients whom tumor biopsies cannot be obtained (e.g., inaccessible tumor or subject safety concern) that may submit an archived tumor specimen only upon agreement from the Sponsor. If feasible, patients will also be given the option of providing a tumor tissue sample at disease progression from metastasis or primary tumor (if tumor biopsies cannot be obtained for inaccessible lesion or subject safety concern)
Willingness and ability to provide blood samples (liquid biopsy) at the time of inclusion, after 2 cycles of study treatment (C3D1), and upon PD or study termination
Adequate organ function
Hematological: White blood cell (WBC) count > 3.0 x 109/L, absolute neutrophil count (ANC) 1.5 x 109/L, platelet count 75.0 x109/L, and hemoglobin > 9.0 g/dL
Hepatic: Bilirubin 1.5 times the upper limit of normal ( ULN) (< 3 x ULN in the case of Gilbert's disease); aspartate transaminase (AST), and alanine transaminase (ALT) 2.5 times ULN (in the case of liver metastases 5 ULN); Albumin > 2.5 mg/mL
Renal: Serum creatinine 1.5 x ULN; alternately measured or calculated creatinine clearance 30 mL/min with creatinine levels >1.5 institutional ULN (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance)
Coagulation: Activated Partial Thromboplastin Time (aPTT) 1.5 X ULN and International Normalized Ratio (INR) or Prothrombin Time (PT) 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 180 days after the last dose of study treatment
Patients that have received prior chemotherapy regimens or radiotherapy for locally recurrent and/or metastatic disease are not excluded but patients nave of systemic treatment can also be included
For pretreated patients, last dose of chemotherapy administered 28 days from study entry

Exclusion Criteria

Locally PSqCC candidate for curative treatment
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Known hypersensitivity to any of the excipients of INCMGA00012
Receipt of anticancer therapy or participation in another interventional clinical study within 28 days before the first administration of study drug; 6 weeks for mitomycin C
Radiotherapy within 14 days of first dose of study treatment with the following caveat: 28 days for pelvic radiotherapy
Toxicity of prior therapy that has not recovered to Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion support). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with Sponsor's medical monitor
Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 4 weeks of start of study drug, or patients who have not recovered from the side effects of any major surgery, or patients who may require major surgery during the study
Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated (e.g., radiotherapy, stereotactic surgery) and are clinically stable off anticonvulsants and steroids for at least 4 weeks before randomization
Cardiovascular: patients that have any of the following within 6 months of randomization: severe/unstable angina, myocardial infarction, symptomatic pericarditis, symptomatic congestive heart failure (New York Heart Association functional classification III-IV), cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism, coronary/peripheral artery bypass graft, ongoing cardiac dysrhythmias of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.5.0 grade 2, including, ventricular arrhythmias -except for benign premature ventricular contractions-, supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication, any conduction abnormality requiring a pacemaker or any cardiac arrhythmia not controlled with medication
Metabolic: Uncontrolled hyper/hypothyroidism or diabetes mellitus type 1 (T1DM). Patients with hypothyroidism stable on hormone replacement will not be excluded from the trial. Patients with controlled T1DM on a stable insulin regimen may be eligible for this study
Diagnosis of immunodeficiency or is receiving systemic steroid therapy or immunosuppressive therapy within seven days prior to study treatment initiation
Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)
Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic steroid
replacement therapy ( 10 mg prednisone daily) for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment
\. Prior allogenic stem cell or solid organ transplantation
\. Has received a live vaccine within 28 days of the planned start of study
drug. Note: Examples of live vaccines include, but are not limited to, the
following: measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies
Bacillus Calmette-Gurin (BCG), and typhoid vaccine. Seasonal influenza
vaccines for injection are generally killed virus vaccines and are allowed
however, intranasal influenza vaccines (e.g., FluMist) are live-attenuated
vaccines and are not allowed
\. Active/history of pneumonitis requiring treatment with steroids or
active/history of interstitial lung disease
\. Active uncontrolled infection at the time of screening
\. Latent tuberculosis determined by a positive TST followed by confirmation
by pulmonologists
\. Participants who are known to be human immunodeficiency virus
(HIV)-positive, unless all of the following criteria are met
CD4-positive count 300/L
Undetectable viral load
Receiving highly active antiretroviral therapy
Active hepatitis A virus (HAV) (positivity for HAV IgM antibody), hepatitis B virus (HBV) (patients with negative hepatitis B surface antigen [HBsAg] test and a positive antibody to HBsAg [anti-HBsAg] test at screening are eligible) or hepatitis C virus (HCV) (patients with a positive antibody to hepatitis C [anti-HCV] are eligible only if polymerase chain reaction [PCR] is negative for virus hepatitis C ribonucleic acid [RNA])
Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for >1 year, after treatment with curative intent
Patients have any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment contraindicate patient participation in the clinical study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note